p.99 抽出テキスト

August 20, 2019 Circulation. 2019;140:e382–e482. DOI: 10.1161/CIR.0000000000000628 e480

CLINICAL STATEMENTS AND GUIDELINES Kusumoto et al 2018 Bradycardia Clinical Practice Guidelines

Keith R. Oken Mayo Clinic— Program Director,

Cardiovascular Diseases Fellowship

and Assistant Professor of Medicine None None None None None None None

Kristen K. Patton University of Washington—

Professor of Medicine None None None None None None None

Cara Pellegrini University of California San Francisco School

of Medicine— Associate Professor •  Abbott •  Medtronic None None None None None 4.3.1, 5, 6, 7, 8, 9, 11, 13

Kimberly A. Selzman University of Utah School of Medicine— Associate Professor

of Medicine None None None None None None None

Annemarie Thompson Duke University

School of Medicine— Professor of Anesthesiology and

Medicine None None None None None None None

Paul D. Varosy VA Eastern Colorado Health

Care System— Director, Cardiac Electrophysiology;

University of Colorado— Associate Professor

of Medicine None None None None None None None

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. CMS reported payments from Cardiofocus to Dr. Kusumoto in 2016 and 2017. Dr. Kusumoto has established that the study he participated in ended in 2014 and was published in 2015. CMS reported consulting payments to Dr. Lee from Abbott, Cryolife and Maquet in 2016. Dr. Lee has established that his participation with the companies ended in January 2015. CMS reported research payments from Medtronic to Dr. McLeod in 2016 and 2017. Dr. McLeod is disputing the payments. *Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers pertain to those in the full-text guideline. †Significant relationship. ‡No financial benefit. ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; HRS, Heart Rhythm Society; UT, University of Texas; VA, Veterans Affairs; and VCU, Virginia Commonwealth University.

Appendix 1.  Continued

Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/

Principal Personal Research Institutional, Organizational,

or Other Financial Benefit Expert Witness Voting Recusals by

Section*

Downloaded from http://ahajournals.org by on October 7, 2026